Biomarin Pharmaceutical Inc (BMRN)

Interest coverage

Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 689,643 850,797 685,960 554,102 407,044 315,083 253,938 205,304 165,948 123,275 87,420 164,953 116,157 71,092 50,355 -60,606 -32,721 -42,050 -94,770 -13,535
Interest expense (ttm) US$ in thousands 10,698 11,087 11,982 12,666 16,187 16,998 17,179 17,335 14,863 15,763 15,867 15,970 16,190 15,381 15,339 15,337 16,240 21,967 26,198 29,309
Interest coverage 64.46 76.74 57.25 43.75 25.15 18.54 14.78 11.84 11.17 7.82 5.51 10.33 7.17 4.62 3.28 -3.95 -2.01 -1.91 -3.62 -0.46

September 30, 2025 calculation

Interest coverage = EBIT (ttm) ÷ Interest expense (ttm)
= $689,643K ÷ $10,698K
= 64.46


Peer comparison

Sep 30, 2025

Company name
Symbol
Interest coverage
Biomarin Pharmaceutical Inc
BMRN
64.46
Arrowhead Pharmaceuticals Inc
ARWR
0.93
Regeneron Pharmaceuticals Inc
REGN
123.21